The effect of the muscarinic M1 receptor antagonist biperiden on cognition in medication free subjects with psychosis

anon79999497 · July 12, 2017, 11:27am

ncbi.nlm.nih.gov

The effect of the muscarinic M1 receptor antagonist biperiden on cognition in medication free subjects with psychosis.

C Vingerhoets, G Bakker, J van Dijk, OJN Bloemen, Y Wang, RCK Chan, J Booij and TAMJ van Amelsvoort, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017 09

The acetylcholine muscarinic M1 receptor has been implicated in both psychosis and cognition. Post-mortem research has shown reduced muscarinic M1 receptor density in 25% of chronic patients with schizophrenia. It is unknown whether reduced M1 receptor density is related to cognitive symptoms of psychosis. We investigated the role of the M1 receptor in separate cognitive domains in subjects with a psychotic disorder using a muscarinic M1 antagonist as an acute pharmacological challenge. 33 young subjects with a psychotic disorder and 30 gender, age and IQ matched healthy controls were enrolled. All participants completed a comprehensive cognitive test battery twice: once after placebo and once after oral administration of 4mg. biperiden (M1 antagonist). The order of drug administration was counterbalanced. Biperiden significantly negatively influenced both verbal (p< 0.001 and p=0.032) and visual learning and memory (p=0.028) in both groups. A medication x group interaction effect was found for reasoning and problem solving (p=0.005). No main or interaction effects were found for other cognitive domains. These results provide further in-vivo evidence that the M1 receptor is involved in cognitive functioning, particularly verbal and visual memory processes. Lack of differential effects of biperiden between psychotic subjects and healthy controls may suggest that decreased M1 receptor density is only present in chronic, older schizophrenia patients. However, it remains possible that differential effects of biperiden would be present in more severe cognitive impaired subjects with psychosis after several doses of biperiden instead of a single administration.

Anon10 · July 13, 2017, 3:26am

Isn’t muscarinic antagonism an anticholinergic action? If so wouldn’t this biperiden medication have negative effects of memory which would show up on tests as a decrease in cognitive performance?

Topic		Replies	Views
Cognitive burden of anticholinergic medications in psychotic disorders News	6	1459	April 10, 2017
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154 News	0	526	July 22, 2017
Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia News	8	1283	May 7, 2016
Rethinking Clozapine: Metabolite May Ease Cognitive Symptoms of Schizophrenia News	0	533	June 15, 2015
A novel M1 PAM VU0486846 exerts efficacy in cognition models without displaying agonist activity or cholinergic toxicity News	3	568	April 29, 2018

The effect of the muscarinic M1 receptor antagonist biperiden on cognition in medication free subjects with psychosis

Related topics